Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.51%
#2 Fake World Assets Fake World Assets +18.28%
#3 Status Status +17.90%
#4 GoPlus Security GoPlus Security +11.51%
#5 Ontology Gas Ontology Gas +10.01%
#6 Bedrock Bedrock +7.70%
#7 DMT-NAT DMT-NAT +7.61%
#8 Cap Cap +6.73%
#9 Provenance Blockchain Provenance Blockchain +6.73%
#10 Janction Janction +5.45%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Rang in Aktien #33997
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Aktienkurs
$0.1502
Zuletzt synchronisiert: 2024-11-04
Marktkapitalisierung
$6.43M
Veränderung (1 Tag)
-5.45%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Renalytix Plc (RNLX)

Kategorie

Healthcare
P/B-Verhältnis für Renalytix Plc (RNLX)
P/B-Verhältnis zum August 2026 TTM: -1.43
Laut den neuesten Finanzberichten und dem Aktienkurs von Renalytix Plc beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) -1.43. Am Ende des Jahres 2023 lag das P/B-Verhältnis bei 6.50.
P/B-Verlauf für Renalytix Plc von 2018 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
2026 (TTM) -1.43 -17.55%
2024 -1.73 -126.57%
2023 6.50 237.16%
2022 1.93 -83.22%
2021 11.50 5.79%
2020 10.87 6.56%
2019 10.20 -100.03%
2018 -30.05K 0.00%
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
 3.0416 -313.25%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
 48.0487 -3,468.77%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
 6.2063 -535.13%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
 21.0676 -1,577.08%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
 - -
US